Acne Therapeutics Market Size& Industry Outlook
The global acne therapeutics market size reached US$ 10.24billion with rise of US$10.74billion in 2024 is expected to reach US$ 17.01billion by 2033, growing at a CAGR of 5.2%during the forecast period 2025-2033.
With rising awareness of personal grooming and skin health, consumers are more proactive in seeking effective acne treatments. Social media, dermatology campaigns, and online education have significantly influenced public understanding of acne management and skincare routines. For instance, campaigns by skincare brands like Neutrogena and Clean & Clear educate young adults and teenagers on daily cleansing, spot treatment, and the importance of early intervention. This heightened awareness drives demand not only for over-the-counter products but also for prescription therapeutics, as consumers increasingly recognize the importance of professional-grade treatments for preventing scarring and managing severe acne.
Key Highlights
North America dominatesthe acne therapeutics market with the largest revenue share of 42.5% in 2024.
The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of9.1% over the forecast period.
Based on therapeutics, retinoids segmented the market with the largest revenue share of 39.1% in 2024.
The major market players in the Allergan Plc, Galderma S.A, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd, Johnson & Johnson, Reckitt Benckiser Group, Stiefel Laboratories, Valeant Pharmaceuticals, Teva Pharmaceuticals, Cutera Inc
Market Dynamics
Drivers: The rising prevalence of acne is significantly driving the acne therapeutics market growth
The rising prevalence of acne plays a central role as a market driver in the global acne therapeutics industry. Acne is one of the most common dermatological conditions, affecting millions of people worldwide, particularly adolescents and young adults. According to the American Academy of Dermatology, acne impacts nearly 85% of individuals between the ages of 12 and 24, making it a leading reason for dermatology visits. This growing patient pool creates a consistent demand for effective treatment options ranging from over-the-counter products to advanced prescription therapies.
Moreover, as lifestyle changes, pollution, stress, and dietary habits further contribute to acne incidence across both developed and developing regions, pharmaceutical companies and skincare brands are expanding their product portfolios to cater to this rising need. This increasing prevalence not only drives sales of conventional treatments like retinoids and antibiotics but also fuels the adoption of innovative solutions such as combination therapies and novel drug delivery systems, thereby accelerating overall market growth.
Restraints: Side effects associated with treatments are hampering the growth of the acne therapeutics market
Side effects associated with treatments represent a significant challenge in the global acne therapeutics market. While prescription medications such as retinoids, antibiotics, and hormonal agents are widely used for managing moderate to severe acne, they often come with undesirable effects that limit patient compliance. For instance, oral isotretinoin, though highly effective, is linked to serious side effects including teratogenicity, liver toxicity, and severe dryness of skin and mucous membranes. Similarly, long-term use of antibiotics can lead to antimicrobial resistance, reducing their effectiveness over time.
For more details on this report – Request for Sample
Segmentation Analysis
The global acne therapeutics market is segmented based on therapeutics, route of administration, distribution channel, and region.
Therapeutics:
The retinoids from therapeutics segment to dominate the acne therapeutics market with a 39.1% share in 2024
The retinoids segment is a significant contributor to the global acne therapeutics market due to its proven effectiveness in treating acne. It promotes faster skin cell turnover, prevents pore blockages, and reduces inflammation, making it suitable for mild and severe cases. The segment's market presence is further strengthened by its use as a first-line therapy in dermatology guidelines. Innovations in advanced formulations and combination therapies minimize side effects and improve patient adherence. The rising awareness of skincare and acne prevalence further boosts demand for retinoid-based therapies.
For instance, in August 2025, Alembic Pharmaceuticals has received final FDA approval to launch Tretinoin Cream USP (0.025%) in the US market, a generic equivalent of Retin-A Cream 0.025% developed by Bausch Health US, LLC. Tretinoin cream is widely prescribed for acne vulgaris treatment and is applied topically.
Route of Administration: The topical segment is estimated to have a 45.1% of the acne therapeutics market share in 2024
The topical route of administration, which is the preferred method for managing mild to moderate acne. Topical formulations like gels, creams, lotions, and foams are easy to apply, have fewer side effects, and are suitable for long-term use, especially among adolescents and young adults. The segment's growth is supported by the availability of both over-the-counter and prescription options, and continuous innovation in topical drug delivery systems, such as microsphere technology and combination formulations. As skincare awareness increases globally, the topical segment remains a reliable driver of the market.
For instance, in July 2025, Cosmo Pharmaceuticals has launched Winlevi (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia. The topical treatment is designed for acne vulgaris in patients aged twelve and older, marking a significant milestone in the partnership between Cosmo and Hyphens Pharma.
Geographical Analysis
North America dominates the global acne therapeutics market with a 42.5% in 2024
North America holds a strong position in the acne therapeutics market due to high acne prevalence, advanced healthcare infrastructure, and strong adoption of prescription and over-the-counter treatments. Growing awareness about skincare, combined with significant investments in dermatology research and product innovation, drives steady demand in this region.
The U.S. leads globally, with a large patient pool, high consumer spending on skincare, and availability of advanced treatment options. The presence of key pharmaceutical and cosmetic companies, along with active promotional campaigns and access to dermatologists, further boosts market growth.
For instance, in July 2025, Sagimet Biosciences has reported that denifanstat, a once-daily oral small molecule fatty acid synthase inhibitor, has met all primary and secondary endpoints in a Phase 3 clinical trial for moderate to severe acne vulgaris in China. The drug, developed by Ascletis Bioscience Co. Ltd., is being used for acne in China and MASH in the rest of the world. Sagimet also initiated a Phase 1 first-in-human clinical trial with a second FASN inhibitor, TVB-3567, for acne in the US.
Europe is the second region after North America which is expected to dominate the global acne therapeutics market with a 34.5% in 2024
In Europe, rising demand for both prescription medications and cosmetic acne solutions is a key driver. Strong regulatory frameworks ensure the availability of safe and effective products, while increasing awareness about skin health and growing use of combination therapies support market expansion.
Germany stands out within Europe due to its high healthcare spending and growing consumer preference for dermatology consultations. The country’s strong pharmaceutical manufacturing base and emphasis on innovative skincare formulations play an important role in driving demand for acne therapeutics.
For instance, in April 2025, Sonoma Pharmaceuticals, Inc., a global healthcare leader, has registered its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA). These products, developed using Microcyn technology, are intended for various applications such as wound care, eye care, and dermatological conditions. They will be sold through a UK health and beauty retailer and pharmacy chain.
The Asia Pacific region is the fastest-growing region in the global acne therapeutics market, with a CAGR of 9.1% in 2024
The Asia-Pacific region is witnessing rapid growth fueled by rising acne incidence among younger populations, growing disposable incomes, and increasing interest in personal grooming. Expanding e-commerce channels and the availability of both global and local skincare brands make treatments more accessible, strengthening this region’s role in the market.
For instance, in July 2025, Hyphens Pharma, a subsidiary of Hyphens Pharma International Limited and one of Singapore’s leading specialty pharmaceutical and consumer healthcare groups, has announced the introduction of Winlevi (clascoterone) cream 1% in Singapore and Malaysia, marking its debut in the Southeast Asian market.
This milestone is enabled through an exclusive licensing and supply agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. The partnership grants Hyphens Pharma rights to Winlevi, along with its future product extensions and enhancements, across 10 Southeast Asian countries, including Singapore, Malaysia, Indonesia, Philippines, Vietnam, Thailand, Brunei, Cambodia, Laos, and Myanmar.
Moreover, in Japan, the acne therapeutics market is supported by a beauty-conscious population, high product awareness, and demand for advanced formulations with fewer side effects. Strong innovation in cosmetic dermatology, along with rising use of over-the-counter solutions, further propels growth in this market.
Competitive Landscape
Top companies in the acne therapeutics market include Allergan Plc, Galderma S.A, Bausch Health Companies Inc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson, Reckitt Benckiser Group, Stiefel Laboratories, Valeant Pharmaceuticals, Teva Pharmaceuticals, Cutera Inc and among others.
Allergan Plc: Allergan Plc is a leading global brand in the acne therapeutics market, known for its innovative treatments that address both medical and cosmetic aspects of acne management. With a strong global distribution network and strategic marketing initiatives, Allergan expands access to acne solutions across multiple regions. The company's expertise in developing advanced formulations and combination therapies has enhanced treatment effectiveness and improved patient adherence.
Key Developments:
In March 2025, Dermata Therapeutics, Inc., a biotechnology company, has reported positive results from its Phase 3 trial of XYNGARI, a topical product for moderate-to-severe acne. The once-weekly product was found to be safe and well-tolerated by patients, with minimal treatment-related adverse events and no serious adverse events attributed to treatment.
Market Scope
Metrics | Details | |
CAGR | 5.2% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Therapeutics | Retinoids, Antibiotics, Hormonal Agents, Anti-inflammatory Agents, Others |
Route of Administration | Oral, Injectables | |
Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | |
Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
The global acne therapeutics market report delivers a detailed analysis with 62 key tables, more than 57visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
For more pharmaceuticals-related reports, please click here
